Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Discontinuation at 28 vs 36 Weeks for Preeclampsia Prevention
NCT06111079Phase 3Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in preeclampsia (2 arms). Primary endpoint: Incidence of preterm preeclampsia. Started Nov 2023; status: recruiting.
02
Drugs
aspirin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT06111079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111079.